SeaCrest Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

SeaCrest Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-921	Closed	-$32K	–	1678
2019 Q1	$32K	Sell	921 -45	-5%	-$1.67K	0.01%	1093
2018 Q4	$32K	Buy	966 +100	+12%	+$4.3K	0.01%	1059
2018 Q3	$44K	Buy	866 +85	+11%	+$4.2K	0.01%	1058
2018 Q2	$47K	Sell	781 -120	-13%	-$6.22K	0.01%	1020
2018 Q1	$41K	Buy	901 +870	+2,806%	+$36.3K	0.01%	1041
2017 Q4	$1K	Buy	+31	New	+$1.23K	﹤0.01%	2143

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

SeaCrest Wealth Management's SUPN Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 921 shares — an estimated $32K sold.

SeaCrest Wealth Management first reported a position in SUPN in Q4 2017 and held it in 6 quarters. The position peaked at $47K in Q2 2018. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

SeaCrest Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 921 Supernus Pharmaceuticals shares in Q2 2019, an estimated $32K.
SeaCrest Wealth Management first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Supernus Pharmaceuticals position peaked at $47K in Q2 2018.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.